CK19和myc mRNA联合检测在乳腺癌诊断中的临床研究

摘要

Objective:To evaluate the clinical application of CK19 and myc gene in the diagnosis of breast cancer by combined detection. Methods:CK19 and myc in 15 health women, 30 patients with benign breast disease and 151 patients with breast cancer were detected by FQ - PCR. β2 - microglobin was used as internal control. Results :There was no significant difference in CK19 and myc/β2 - microglobin between normal controls and benign breast disease group( P ＞ 0.05 ). CK19 and nyc/β2 - microglobin in breast cancer group were higher than those in the other groups ( P ＜ 0.05 ). There was no difference in β2 - microglobin among three groups( P ＞ 0.05 ). The sensitivity of CK19 and nyc gene express by combined detection was higher than that of single gene detection. Conclusions :FQ -PCR is a rapid and sensitive and specific method for testing CK19 and myc. The combined detection can improve the sensitivity of diagnosis in breast cancer.%目的:建立荧光定量聚合酶链反应(FQ-PCR)法检测细胞角蛋白19(CK19)和myc基因表达水平,探讨其联合检测在乳腺癌诊断和治疗监测中的应用.方法:建立FQ-PCR法,并以β2-微球蛋白为内对照测定15名健康女性体检者、30例良性乳腺疾病患者和151例乳腺癌患者外周血中CK19和myc的表达量.结果:CK19和myc表达水平在正常对照组和良性乳腺疾病组间差异无显著性意义(P＞0.05),乳腺癌组均高于前两组(P＜0.05),β2-微球蛋白在三组间差异无显著性意义(P＞0.05).CK19和myc联合检测的灵敏度高于单个基因的检测.结论:FQ-PCR技术是高度灵敏、高度特异的快速定量检测CK19和myc方法,两者联合检测可有效提高对乳腺癌诊断的灵敏度.